Riskpilot← Back to searchSign inGet full accessOctarine Bio ApS
APSActiveCVR 39857316Lersø Parkallé 42, 1.Research and experimental development on natural sciences and engineering · NACE 7210Est. 201819 employeeswww.octarinebio.com
Revenue 2024
DKK 388K
-64% vs 2023
EBITDA margin
-5617.4%
-71% vs 2023
Equity ratio
-160.3%
Financial strength
Net profit 2024
DKK -22,3M
-16% vs 2023
| Revenue | DKK 388K | -64% |
| EBITDA | DKK -21,8M | -71% |
| Net profit | DKK -22,3M | -16% |
| Total assets | DKK 27,9M | -20% |
| Equity | DKK -44,7M | -99% |
| Employees | 19 | — |
Legal name
Octarine Bio ApS
CVR number
39857316
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12. september 2018
Share capital
DKK 110.436
Employees
19 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem og en direktør i forening eller af den samlede bestyrelse
Company purpose
1.2 Selskabets formål er at drive forsknings- og udviklingsvirksomhed indenfor sundhed og kosmetisk pleje og hermed beslægtet virksomhed.
Address
Lersø Parkallé 42, 1.
Phone
+4527639353
Email
info@octarinebio.com
Website
www.octarinebio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 917 | 1.682 | 1.378 | 1.089 | 388 |
| Staff expenses | -2.162 | -4.769 | -5.751 | -6.056 | -7.792 |
| EBITDA | -1.735 | -4.502 | -6.667 | -12.762 | -21.788 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -1.735 | -4.502 | -6.667 | -12.762 | -21.788 |
| Net financials | 30 | -308 | -927 | -1.986 | -4.764 |
| Profit before tax | -1.705 | -4.810 | -7.594 | -14.748 | -26.552 |
| Tax | 668 | 1.609 | 2.077 | 4.544 | -4.253 |
| Net profit | -2.373 | -6.419 | -9.671 | -19.292 | -22.299 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 9.332 | 14.676 | 15.340 | 34.789 | 27.908 |
| Equity | -900 | 6.527 | -3.145 | -22.437 | -44.736 |
| Long-term debt | 5.484 | 3.029 | 3.476 | 3.428 | 3.741 |
| Short-term debt | 4.748 | 5.121 | 15.008 | 53.798 | 68.903 |
| Total debt | 10.232 | 8.149 | 18.485 | 57.226 | 72.644 |
EBITDA margin
-5617.4%
This company
15.8%
Market median
-35653% vs market
20202024
Equity ratio
-160.3%
This company
38.2%
Market median
-520% vs market
20202024
Return on equity
-2229875100.0%
This company
18.4%
Market median
-12118886513% vs market
20202024
Net profit margin
-5749.1%
This company
8.1%
Market median
-71077% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
1.62×
This company
0.62×
Market median
-161% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NJ Chief Executive Officer | Chief Executive Officer | 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2021 | |
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Former (3) | ||
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 15–19.99% | 15–19.99% | 2025 | |
| Individual | 10–14.99% | 10–14.99% | 2025 | |
| Company | 10–14.99% | 10–14.99% | 2025 | |
| Company | 5–9.99% | 5–9.99% | 2025 | |
| Individual | 5–9.99% | 5–9.99% | 2025 | |
| Company | 5–9.99% | 5–9.99% | 2025 | |
| Individual | 5–9.99% | 5–9.99% | 2025 | |
| Individual | 5–9.99% | 5–9.99% | 2025 | |
| Company | 10–14.99% | 10–14.99% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Biosphere ApS
Octarine Bio ApS Board members of Octarine Bio ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nethaji Janeshawari Gallage | Chief Executive Officer | 0 companies |
| Akshat Kshetrapal | Board of Directors | 0 companies |
| Stephan Christgau | Chairman | 0 companies |
| Lene Gerlach | Board of Directors | 0 companies |
| Alexandre Ouimet-Storrs | Board of Directors | 0 companies |
| Marianne Tochtermann | Board of Directors | 0 companies |
| Christian Brix Tillegreen | Board of Directors | 0 companies |
| Helga Claudia Blomgren-Hansen | Board of Directors | 0 companies |
| Jonas Ahm-Lundgren | Board of Directors | 0 companies |